14 December 2020 - In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), now recommending the drug's NHS use in a Final Appraisal Document on the back of further analysis submitted by the company.

If a final green light follows this decision, people in England and Wales living with four or more migraine days per month, for whom at least three prior preventive drug treatments have failed, will get routine access to this treatment through the NHS.

Read Pharma Times article